Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.56 |
| ▸ | MMP9 | P14780 | 3/20 | 0.56 |
| ▸ | PLAU | P00749 | 5/20 | 0.47 |
| ▸ | HPN | P05981 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 4/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284484 | 1.00 | MMP2 (0.56) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL284482 | 0.87 | MMP2 (0.53) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL1421131 | 0.87 | MMP2 (0.53) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL28509074 | 0.86 | MMP2 (0.60) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL8965842 | 0.85 | MMP9 (0.65) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL457772 | 0.85 | MMP9 (0.76) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL10585071 | 0.85 | MMP9 (0.76) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL6893970 | 0.85 | MMP2 (0.61) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL8001084 | 0.85 | MMP9 (0.76) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL200247 | 0.84 | MMP2 (0.57) | MMP2MMP9PLAUHPNTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146930-A1 | 177-LU LABELED ACTIVE SITE INHIBITED FACTOR VII | MINERVA IMAGING APS (DK) | 2023-05-11 | — | — | US | disclosed |
| EP-3402537-B1 | QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABELLED ACTIVE SITE INHIBITED FACTOR VII | RIGSHOSPITALET (DK) | 2021-01-06 | — | — | EP | disclosed |
| US-10577639-B2 | Rapid bed-side measurement of neutrophil elastase activity in biological fluids | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3541432-A1 | 177-LU LABELED ACTIVE SITE INHIBITED FACTOR VII | Minerva Imaging ApS (DK) | 2019-09-25 | — | — | EP | disclosed |
| US-20190015532-A1 | QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABLED ACTIVE SITE INHIBITED FACTOR VII | MINERVA IMAGING APS (DK) | 2019-01-17 | — | — | US | disclosed |
| EP-3402537-A1 | QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABLED ACTIVE SITE INHIBITED FACTOR VII | Rigshospitalet (DK) | 2018-11-21 | — | — | EP | disclosed |
| WO-2018091058-A1 | 177-LU LABELED ACTIVE SITE INHIBITED FACTOR VII | RIGSHOSPITALET (DK) | 2018-05-24 | — | — | WO | disclosed |
| US-20180000899-A1 | MODIFYING MACROPHAGE PHENOTYPE FOR TREATMENT OF DISEASE | APELLIS PHARMACEUTICALS, INC. | 2018-01-04 | — | — | US | disclosed |
| WO-2017121436-A1 | QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABLED ACTIVE SITE INHIBITED FACTOR VII | RIGSHOSPITALET (DK) | 2017-07-20 | — | — | WO | disclosed |
| EP-1497307-B1 | RECOMBINANT P.FALCIPARUM MEROZOITE PROTEIN-1 42 VACCINE | US ARMY (US) | 2016-08-03 | — | — | EP | disclosed |
| WO-2003084472-A2 | RECOMBINANT P. FALCIPARUM MEROZOITE PROTEIN-142 VACCINE | WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003076461-A2 | DIMERIC TF ANTAGONIST COMPRISING TWO FACTOR VII POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2003-09-18 | — | — | WO | disclosed |
| WO-2001051067-A1 | MULTIPLE INACTIVATED BLOOD FACTOR ANTICOAGULANT COMPOSITION | BAXTER INTERNATIONAL INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001021661-A1 | BIVALENT INHIBITOR OF FVIIa/TF/FXa COMPLEX | NOVO NORDISK A/S (DK) | 2001-03-29 | — | — | WO | disclosed |
| US-4762789-A | THIOL PROTEINASE | THE UNIVERSITY OF CALIFORNIA (US) | 1988-08-09 | — | — | US | disclosed |
| EP-0182906-A1 | HUMAN LEUKOCYTE ELASTASE INHIBITORS PREPARED FROM PYOGENIC BACTERIA AND METHODS FOR THEIR PURIFICATION | CORTECH, INC. (US) | 1986-06-04 | — | — | EP | disclosed |
| WO-1986000077-A1 | HUMAN LEUKOCYTE ELASTASE INHIBITORS PREPARED FROM PYOGENIC BACTERIA AND METHODS FOR THEIR PURIFICATION | CORTECH, INC. (US) | 1986-01-03 | — | — | WO | disclosed |
| US-4368186-A | ETHYLENE OXIDE-PROPYLENE OXIDE BLOCK COPOLYMER AND SPERMICIDE | SYNTEX (U.S.A.) INC. (US) | 1983-01-11 | — | — | US | disclosed |
| EP-0065385-A2 | Methods and compositions for intravaginal contraception | SYNTEX (U.S.A.) INC. (US) | 1982-11-24 | — | — | EP | disclosed |
| US-4016258-A | SYSTEMIC VASODILATION, HYPOTENSION | RESEARCH CORPORATION | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190015532-A1 | QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABLED ACTIVE SITE INHIBITED FACTOR VII | F13B, F7, F13A1 | MMP2 113/4885MMP9 123/4885PLAU 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.